As AstraZeneca’s share price drops 13% should I buy on the dip?

AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and earnings prospects remain high.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Abstract bull climbing indicators on stock chart

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

How quickly things have changed for AstraZeneca’s (LSE: AZN) share price.

Just last month, it had risen sufficiently to make the firm the first in the UK with a market capitalisation of £200bn+.

Now it has dropped 13% from its 3 September 12-month traded high of £133.38.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

However, as a former investment bank trader, the mere fact of it falling – or rising – is irrelevant to my investment decision.

The only question I ever ask nowadays is whether there is any value in a particular stock. If there is, then I will decide whether it suits my current investment criteria overall.

Is there any value in this stock?

My first step here is to look at a key relative stock valuation measure, such as the price-to-earnings ratio (P/E).

AstraZeneca currently trades at a P/E of 37.2. This is the bottom of its competitor group, which has an average P/E of 65. So, it is very undervalued on this basis.

The same applies to the other two key relative valuation ratios I use – price-to-book (P/B) and price-to-sales (P/S).

It trades at a P/B of just 6.1 against a peer average of 37.8. And it has a P/S of 4.9 compared to the 13.3 group average.

To work out what these undervaluations mean in cash terms, I ran a discounted cash flow analysis.

This shows AstraZeneca shares to be 51% undervalued at their current £115.55.

So a fair price would be £235.82, although they may go lower or higher than that. In any event, the answer for me is that there is huge value in the stock.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL26 Sep 201926 Sep 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

So why’s it down?

The key driver for the recent price loss was disappointing trial results for its Datopotamab deruxtecan (Dato-DXd) drug. These showed that it failed to significantly extend the lives of breast cancer patients.

However, the firm has since said there is evidence the drug offers value for patients. Consequently, it will continue discussions with regulators about its use.

Any such failure is a blow to a pharmaceutical firm. Future failures on any of its major drugs remain a key risk to AstraZeneca, being costly in time and money.

That said, AstraZeneca already has another breast cancer treatment drug – Enhertu – already approved and on sale, regardless of what happens with Dato-DXd.

Additionally positive is the 23 September announcement that its Fasenra asthma medicine has been recommended for approval in the European Union.

And on 20 September, the US FDA approved AstraZeneca’s FluMist influenza nasal spray vaccine for self-administration. This is the first of its kind that patients can give themselves.

What’s the growth outlook from here?

In its 21 May ‘Ambition 2030 and Beyond’ presentation, the firm said it will achieve $80bn+ in revenues by 2030. This compares to $45.8bn at the end of 2023.

It also said at that point that it is on track to deliver mid-30% core operating margin by 2026. It will target at least mid-30% after that, subject to the development of its portfolio.

As it stands – even after the disappointing Dato-DXd trials –analysts forecast that AstraZeneca’s earnings will grow 16.4% a year to end-2026.

My view

I already hold the shares, which I bought for their significant undervaluation and strong growth prospects. Nothing has changed in my view, so I will buy more very soon.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

The Next share price is up 36% in a decade. Should I buy now for the next decade?

The Next share price has risen over the past decades. Our writer explains why he doesn't regret not investing then…

Read more »

Investing Articles

How an investor could target a passive income of £2,747 a year from just £2k of savings!

Harvey Jones shows how it's possible to generate a high and rising passive income stream from a relatively small initial…

Read more »

Investing Articles

With £2k an investor could consider buying these cheap shares in March

Harvey Jones has been scouring the FTSE 100 for cheap shares, and these stocks caught his eye. He thinks Barclays…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Dividend Shares

Down 30%, this FTSE 250 stock has an 11% dividend yield! I’m tempted

Jon Smith scratches his head as he looks over a FTSE 250 company with a juicy dividend yield but a…

Read more »

Growth Shares

Has the IAG share price peaked already for 2025?

Jon Smith explains why some investors are concerned about the short-term drop in the IAG share price but flags up…

Read more »

Investing Articles

The Lloyds share price is already up 24% in 2025! Can it hit £1?

Christopher Ruane thinks the Lloyds share price may move higher still, but he's sceptical as to whether it might hit…

Read more »

Investing Articles

This is the worst FTSE 100 stock of 2025 so far. Should I buy it?

This FTSE 100 stock has been stinking out the blue-chip UK index this year. But after its slump, it now…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

Are Diageo shares the ultimate recovery play?

It has been one bit of bad news after another for the FTSE 100 drinks giant, but Christopher Ruane has…

Read more »